The Cardiovascular Market Outlook to 2014' is a new report that provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players. Furthermore, it highlights the key market and R&D trends that may influence treatment sales; with a thorough analysis of the competitive dynamics of leading brands within each indication, in order to enable the reader to identify growth brands, key drug classes and leading players through 2014.
For more information or to purchase this report, go to:
- http://www.fastmr.com/
Partial Table of Contents:
The Cardiovascular Market Outlook to 2014
Executive summary 12
Overview and epidemiology of cardiovascular disorders 12
Global market analysis 12
Pipeline analysis 13
Competitive landscape 14
Scope and methodology 16
Scope 16
Methodology 17
Chapter 1 Overview and epidemiology of cardiovascular disorders 20
Summary 20
Introduction 20
Predisposing factors 21
Risk factors 24
Hypertension 24
Diagnosis, treatment and management 25
Epidemiology 27
Forecast epidemiology 28
Dyslipidemia 29
Diagnosis, treatment and management 30
Epidemiology 33
Forecast epidemiology 34
Cardiovascular diseases 35
Arteriosclerosis/
Thrombosis 35
Cardiac arrhythmias 35
Myocardial infarction (MI) 36
Acute coronary syndrome (ACS) 36
Congestive heart failure (CHF) 36
Coronary artery disease (CAD) 36
Peripheral artery disease (PAD) 36
Pulmonary hypertension 36
Angina pectoris 37
Stroke 37
Epidemiology 38
Forecast epidemiology 39
Chapter 2 Global market analysis 42
Summary 42
Introduction 43
Market analysis by country 44
Key events in the cardiovascular market 48
Wider indications for Crestor 48
Evolving dynamics of the cholesterol market - patent expirations but an increasing patient base 49
Heightened interest in the HDL cholesterol market 49
ARBs a growing hypertension drug class 49
Tekturna/Rasilez uptake slower than expected 50
Micardis label expansion in the EU 50
Market analysis by drug class 51
Antihypertensive treatments 52
Introduction 52
Different classes of antihypertensives 53
Leading treatment brands by drug class 54
Key brands analysis 56
Diovan/Co-Diovan 56
Norvasc 57
Cozaar 58
Trends in generics usage 59
Antidyslipidemics 60
Introduction 60
Antidyslipidemics drug classes 61
Leading treatment brands by drug class 62
Key brands analysis 64
Lipitor 64
Crestor 66
Trends in generics usage 70
Antithrombotics treatments 71
Introduction 71
Antithrombotics drug classes 72
Leading treatment brands by drug class 73
Key brands analysis 74
Plavix 74
Lovenox 77
Trends in generics usage 78
Other cardiovascular agents 79
Introduction 79
Leading brands by drug class 79
Key brands analysis 80
Tracleer 80
Trends in generics usage 82
Cardiac therapies 82
Introduction 82
Market analysis by drug class 83
Leading treatment brands by drug class 84
Trends in generics usage 85
Cardiovascular sales forecast to 2014 86
Leading brands dynamics 87
Chapter 3 Pipeline analysis 90
Summary 90
Introduction 91
Key events in the cardiovascular market 91
BMS/Pfizer's apixaban is on track for EU regulatory submission in venous
thromboembolism (VTE) 91
Plavix receives a US warning on omeprazole interaction 91
Mipomersen from Genzyme may become a novel option for high cholesterol 92
New treatments drive robust growth of the anticoagulants class 92
Persistent interest in drugs which increase HDL cholesterol levels 93
Valturna remains the first hypertension combination drug to receive US approval 94
NICE drafts guidelines on hypertension treatment in pregnancy 95
Cardiovascular pipeline 96
Leading drugs in development 98
Profiles of key pipeline products 99
Recently approved/launched drugs 99
Pradaxa/Rendix (dabigatran)
Multaq (dronedarone)
Xarelto (rivaroxaban)
Effient/Efient (prasugrel) - Eli Lilly/Daiichi Sankyo 104
Recently filed/pre-registration compounds 106
Apixaban - Bristol-Myers Squibb (BMS)/Pfizer 106
Full ToC is available at:
-- http://www.fastmr.com/
About Business Insights
Business Insights appreciate the importance of accurate, up-to-date incisive market and company analysis and their aim therefore is to provide a single, off-the-shelf, objective source of data, analysis and market insight. Business Insights work in association with leading industry experts to produce a range of reports across a wide range of industry sectors. By working in association with so many experts they are able to provide clients with more incisive market analysis specific to the client's industry sector. No other market analysis company provides such focused and trusted market analysis, across such a wide range of industry sectors. View more research from Business Insights at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
